Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
67.8M
-
Shares change
-
+489K
-
Total reported value, excl. options
-
$7.73B
-
Value change
-
+$50M
-
Put/Call ratio
-
0.38
-
Number of buys
-
123
-
Number of sells
-
-127
-
Price
-
$113.86
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2021
303 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.8M shares
of 96M outstanding shares and own 70.7% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (10.7M shares), Capital Research Global Investors (7.37M shares), VANGUARD GROUP INC (5.89M shares), BlackRock Inc. (5.46M shares), Capital International Investors (5.42M shares), FEDERATED HERMES, INC. (3.91M shares), Capital World Investors (2.77M shares), Clearbridge Investments, LLC (1.9M shares), STATE STREET CORP (1.61M shares), and ALKEON CAPITAL MANAGEMENT LLC (1.31M shares).
This table shows the top 249 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.